Institutional members access full text with Ovid®

Share this article on:

What did we learn on host's genetics by studying large cohorts of HIV-1-infected patients in the genome-wide association era?

Guergnon, Juliena; Theodorou, Ioannisa,b

Current Opinion in HIV and AIDS: July 2011 - Volume 6 - Issue 4 - p 290–296
doi: 10.1097/COH.0b013e3283478449
Cohort analysis of clinical and treatment outcomes: Edited by Carolyn Williams, Matthew Law and François Dabis

Purpose of review Genome-wide association studies (GWASs) performed in large cohorts of HIV-1-infected patients have shown that high throughput genomics can add valuable information in understanding disease progression. We report recent information gathered in the international field during the last few years and revisit the importance of well documented cohorts for genotype–phenotype association studies.

Recent findings The majority of GWASs in the HIV-1 field found that viral loads and disease progression are under the control of variants located in the major histocompatibility complex (MHC) in untreated patients. Although these experiments brought a new and more objective vision of genotype–phenotype correlations in HIV-1 disease, they also pointed out that less than 15% of the observed phenotypic variability can be explained as common genetic variants. Most of the studies have included mainly white patients and the few studies performed in Africans are underpowered but suggest that MHC is probably not the only genetic determinant influencing disease progression in this population.

Summary Although the first results of the GWASs in HIV disease look as a confirmation of previous findings, high throughput agnostic genomics entered the field of chronic infectious diseases and will probably unveil new genotype–phenotype associations in the future. Networks between existing cohorts leading to ‘virtual mega-cohorts’ will be necessary to increase the probability to discover new genetic pathways important for HIV disease. Finally, predictive models including genetic information for clinical usage is another challenge in HIV disease genetics.

aLaboratory of Immunity and Infection, INSERM UMR-S 945, UPMC Univ Paris 06, France

bGroupe Hospitalier Pitié-Salpêtrière AP-HP, Paris, France

Correspondence to Ioannis Theodorou, MD, Laboratoire d'Immunologie Cellulaire et Tissulaire, Groupe Hospitalier Pitié-Salpêtrière, 83 Boulevard de l'Hôpital, 75013 Paris, France Tel: +33 142 177 511; fax: +33 142 177 490; e-mail:

© 2011 Lippincott Williams & Wilkins, Inc.